Abstract
The Omicron (B.1.1.529) variant of SARS-CoV-2 rapidly achieved global dissemination following its emergence in southern Africa in November, 2021.1,2 Epidemiologic surveillance in multiple settings has revealed changes in COVID-19 case-to-hospitalization and case-to-mortality ratios following Omicron variant emergence.3–7 However, interpretation of these changes is difficult due to potential differences in immunity among cases with Omicron or Delta (B.1.617.2) variant SARS-CoV-2 infections, as well as possible longer-term changes in testing and other healthcare practices.8 Here we report clinical outcomes and characteristics of 228,594 cases with Omicron variant infections and 42,515 cases with Delta variant infections within the Kaiser Permanente Southern California healthcare system, who were followed longitudinally from an initial outpatient test during a period of mixed circulation of the Omicron and Delta variants. Adjusted hazard ratios of progression to symptomatic hospital admission, intensive care unit admission, mechanical ventilation, and death were 0.62 (95% confidence interval: 0.54-0.72), 0.59 (0.51-0.69), 0.45 (0.26-0.78), and 0.36 (0.18-0.74), and 0.21 (0.10-0.42) respectively, for cases with Omicron versus Delta variant infections. These differences in risk of severe clinical endpoints were most pronounced among individuals who had not received any vaccination against COVID-19, owing to partial vaccine protection against severe disease associated with both Omicron and Delta variant infections. Among hospitalized symptomatic cases, average duration of hospital stay was 70.7% (64.4-76.0%) shorter among patients with Omicron as compared to Delta variant infections. These findings demonstrate that the Omicron SARS-CoV-2 variant is associated with substantially severity of illness in comparison to the Delta variant.
Competing Interest Statement
JAL discloses receipt of grants from Pfizer and Merck, Sharp & Dohme, and consulting fees from Pfizer, Merck, Sharp & Dohme, and VaxCyte, Inc., unrelated to this work. SYT discloses receipt of grants from Pfizer unrelated to this work. ML reports grants from CDC, grants from NIH, grants from UK NIHR, grants from Pfizer, personal fees from Merck, personal fees from Janssen, personal fees from Sanofi Pasteur, personal fees from Bristol Myers Squibb, personal fees from Peter Diamandis/Abundance Platinum, outside the submitted work; and Unpaid advice to One Day Sooner, Pfizer, Janssen, Astra-Zeneca, Covaxx (United Biomedical). VXH, MMP, and RK have no competing interests to disclose.
Funding Statement
The study was funded by the US Centers for Disease Control and Prevention.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was reviewed and approved by the Kaiser Permanente Southern California Institutional Review Board, which waived requirement for informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Requests for access to data should be submitted to Sara.Y.Tartof{at}kp.org.
